USPTO Patent Grant: Tumor Treatment with Antibodies
Summary
The USPTO has granted patent US12582713B2 to Bristol-Myers Squibb Company for methods of treating tumors using pharmaceutical compositions containing anti-PD-1 or anti-PD-L1 antibodies, particularly for subcutaneous delivery. The patent also covers compositions that include an endoglycosidase hydrolase enzyme.
What changed
The United States Patent and Trademark Office (USPTO) has issued patent US12582713B2, assigned to Bristol-Myers Squibb Company. This patent covers methods for treating tumors using pharmaceutical compositions that include an anti-PD-1 or anti-PD-L1 antibody. Specific aspects of the disclosure relate to formulations designed for subcutaneous delivery and compositions that incorporate an endoglycosidase hydrolase enzyme.
This patent grant is primarily an intellectual property notification and does not impose new regulatory obligations on drug manufacturers or healthcare providers. However, it signifies exclusive rights for Bristol-Myers Squibb in the patented technology, potentially impacting future research, development, and commercialization strategies in the oncology therapeutic space. Compliance officers in the pharmaceutical sector should note this as a development in the competitive landscape for cancer treatments.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods of treating tumors
Grant US12582713B2 Kind: B2 Mar 24, 2026
Assignee
Bristol-Myers Squibb Company
Inventors
Masano Huang, Thomas Arthur Haby, Mehrnaz Khossravi, Scott Aaron Hart, Rao Venkatramana Mantri, Heather Elizabeth Vezina, Amit Roy, Bindu Purnima Murthy, Urvi Ashish Aras, Kinjal Sanghavi, Xiaochen Zhao, Akintunde Bello
Abstract
The disclosure provides pharmaceutical compositions comprising an anti-PD-1 antibody or an anti-PD-L1 antibody. In some aspects, the pharmaceutical compositions are formulated for subcutaneous delivery. In some aspects, the pharmaceutical compositions further comprise an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering a pharmaceutical composition comprising an anti-PD-1 antibody or an anti-PD-L1 antibody.
CPC Classifications
A61K 39/3955 A61K 9/0019 A61K 38/47 A61K 2039/505 A61P 35/00
Filing Date
2024-01-25
Application No.
18423089
Claims
30
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.